Opus Genetics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Opus Genetics (NASDAQ:IRD) Full Year 2024 Results

Key Financial Results

• Revenue: US$11.0m (down 42% from FY 2023).
• Net loss: US$57.5m (loss widened by 476% from FY 2023).
• US$2.15 loss per share (further deteriorated from US$0.46 loss in FY 2023).

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Opus Genetics Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 9.0%. Earnings per share (EPS) missed analyst estimates by 92%.

Looking ahead, revenue is forecast to grow 30% p.a. on average during the next 3 years, compared to a 8.4% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are down 19% from a week ago.

Risk Analysis

It's necessary to consider the ever-present spectre of investment risk. We've identified 4 warning signs with Opus Genetics (at least 1 which doesn't sit too well with us), and understanding them should be part of your investment process.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.